

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of
Invention

Methods for Detecting Markers Associated with Endometrial Disease or Phase
(US 10/584,207; National Phase Entry of PCT/CA2004/002172)

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. PCT/CA2004/002172 filed on December 21, 2004
☐ As amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: TERENCE J. COLGAN

Date: OCT. 10/07

Signature: T. Colgan

Citizen of: CANADA

Inventor two: K.W. MICHAEL SIU

Date: OCT. 10, 2007

Signature: K.W. Michael Siu


Citizen of: CANADA

☒ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 116 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**SUPPLEMENTAL SHEET TO
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Methods for Detecting Markers Associated with Endometrial Disease or Phase
-----------------------	--

FULL NAME OF INVENTOR(S)	
Inventor Three: <u>ALEXANDER D. ROMASCHIN</u> Signature: _____	Date: _____ Citizen of: <u>CANADA</u>
Inventor Four: <u>ERIC C.C. YANG</u> Signature: _____	Date: _____ Citizen of: <u>CANADA</u>
Inventor Five: <u>LEROI DESOUZA</u> Signature: 	Date: <u>10th Oct '07</u> Citizen of: <u>CANADA</u>
Inventor Six: <u>GEORG DIEHL</u> Signature: _____	Date: _____ Citizen of: _____
Inventor Seven: <u>JINGZHONG GUO</u> Signature: _____	Date: _____ Citizen of: _____

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of
Invention

Methods for Detecting Markers Associated with Endometrial Disease or Phase
(US 10/584,207: National Phase Entry of PCT/CA2004/002172)

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. PCT/CA2004/002172 filed on December 21, 2004
☐ As amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: TERENCE J. COLGAN

Date: _____

Signature: _____

Citizen of: CANADA

Inventor two: K.W. MICHAEL SIU

Date: March 2, 2007

Signature: _____

Citizen of: CANADA


☒ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**SUPPLEMENTAL SHEET TO
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Methods for Detecting Markers Associated with Endometrial Disease or Phase
-----------------------	--

FULL NAME OF INVENTOR(S)	
Inventor Three: <u>ALEXANDER D. ROMASCHIN</u>	Date: <u>Nov 8/07</u>
Signature: <u></u>	Citizen of: <u>CANADA</u>
Inventor Four: <u>ERIC C.C. YANG</u>	Date: _____
Signature: _____	Citizen of: <u>CANADA</u>
Inventor Five: <u>LEROI DESOUZA</u>	Date: _____
Signature: _____	Citizen of: _____
Inventor Six: <u>GEORG DIEHL</u>	Date: _____
Signature: _____	Citizen of: _____
Inventor Seven: <u>JINGZHONG GUO</u>	Date: _____
Signature: _____	Citizen of: _____


**SUPPLEMENTAL SHEET TO
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Methods for Detecting Markers Associated with Endometrial Disease or Phase
--------------------	--

FULL NAME OF INVENTOR(S)	
Inventor Three: <u>ALEXANDER D. ROMASCHIN</u>	Date: _____
Signature: _____	Citizen of: <u>CANADA</u>
Inventor Four: <u>ERIC C.C. YANG</u>	Date: <u>Nov 5, 2007</u>
Signature: <u>Eric Yang</u>	Citizen of: <u>CANADA</u>
Inventor Five: <u>LEROI DESOUZA</u>	Date: _____
Signature: _____	Citizen of: _____
Inventor Six: <u>GEORG DIEHL</u>	Date: _____
Signature: _____	Citizen of: _____
Inventor Seven: <u>JINGZHONG GUO</u>	Date: _____
Signature: _____	Citizen of: _____


**SUPPLEMENTAL SHEET TO
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Methods for Detecting Markers Associated with Endometrial Disease or Phase
--------------------	--

FULL NAME OF INVENTOR(S)	
Inventor Three: <u>ALEXANDER D. ROMASCHIN</u>	Date: _____
Signature: _____	Citizen of: <u>CANADA</u>
Inventor Four: <u>ERIC C.C. YANG</u>	Date: _____
Signature: _____	Citizen of: <u>CANADA</u>
Inventor Five: <u>LEROI DESOUZA</u>	Date: <u>7th Nov 07</u>
Signature: 	Citizen of: <u>CANADA</u>
Inventor Six: <u>GEORG DIEHL</u>	Date: _____
Signature: _____	Citizen of: _____
Inventor Seven: <u>JINGZHONG GUO</u>	Date: _____
Signature: _____	Citizen of: _____

**SUPPLEMENTAL SHEET TO
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Methods for Detecting Markers Associated with Endometrial Disease or Phase
--------------------	--

FULL NAME OF INVENTOR(S)	
Inventor Three: <u>ALEXANDER D. ROMASCHIN</u> Date: _____	
Signature: _____	Citizen of: <u>CANADA</u>
Inventor Four: <u>ERIC C.C. YANG</u> Date: _____	
Signature: _____	Citizen of: <u>CANADA</u>
Inventor Five: <u>LEROI DESOUZA</u> Date: _____	
Signature: _____	Citizen of: _____
Inventor Six: <u>GEORG DIEHL</u> Date: <u>Nov 7, 2007</u>	
Signature: <u></u>	Citizen of: <u>GERMANY</u>
Inventor Seven: <u>JINGZHONG GUO</u> Date: _____	
Signature: _____	Citizen of: _____

**SUPPLEMENTAL SHEET TO
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Methods for Detecting Markers Associated with Endometrial Disease or Phase
-----------------------	--

FULL NAME OF INVENTOR(S)	
Inventor Three: <u>ALEXANDER D. ROMASCHIN</u> Signature: _____	Date: _____ Citizen of: <u>CANADA</u>
Inventor Four: <u>ERIC C.C. YANG</u> Signature: _____	Date: _____ Citizen of: <u>CANADA</u>
Inventor Five: <u>LEROI DESOUZA</u> Signature: _____	Date: _____ Citizen of: _____
Inventor Six: <u>GEORG DIEHL</u> Signature: _____	Date: _____ Citizen of: _____
Inventor Seven: <u>JINGZHONG GUO</u> Signature: <u>Jingzhong Guo</u>	Date: <u>Nov. 7, 2007</u> Citizen of: <u>Canada</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: COLGAN, Terence J., *et al.*
Title: METHODS FOR DETECTING MARKERS
ASSOCIATED WITH ENDOMETRIAL DISEASE OR
PHASE
Application No.: 10/584,207
Filed: June 23, 2006
International Application No. PCT/CA2004/002172

**STATEMENT BY PERSON BEING ADDED AS INVENTOR
(37 C.F.R. § 1.497(d))**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.

Sir:

This communication is an attachment to a Declaration concurrently being filed pursuant to 35 U.S.C. 371 (c)(4) and 37 C.F.R. 1.497 in connection with the above-identified application.

I, Leroi DeSouza, residing at 325 Rancee Avenue, North York, Ontario M6A 1N9, Canada, who is being added as an inventor to correct the inventorship of this patent application do hereby declare that the inventorship error in failing to include my name as an inventor in International Application No. PCT/CA2004/002172 occurred without any deceptive intention on my part.

Date: 7th Nov, 2007

Signature: 
Leroi DeSouza

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: COLGAN, Terence J., *et al.*
Title: METHODS FOR DETECTING MARKERS
ASSOCIATED WITH ENDOMETRIAL DISEASE OR
PHASE
Application No.: 10/584,207
Filed: June 23, 2006
International Application No. PCT/CA2004/002172

**STATEMENT BY PERSON BEING ADDED AS INVENTOR
(37 C.F.R. § 1.497(d))**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.

Sir:

This communication is an attachment to a Declaration concurrently being filed pursuant to 35 U.S.C. 371 (c)(4) and 37 C.F.R. 1.497 in connection with the above-identified application.

J.G. 309-595 Marcel-Laurin Blvd., *H4M2M1* *J.G.*
I, Jingzhong Guo, residing at ~~7-1719 rue Rochon~~, Saint-Laurent, Quebec ~~H4L 1W9~~, Canada, who is being added as an inventor to correct the inventorship of this patent application do hereby declare that the inventorship error in failing to include my name as an inventor in International Application No. PCT/CA2004/002172 occurred without any deceptive intention on my part.

Date: Nov. 7, 2007

Signature: Jingzhong Guo
Jingzhong Guo

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: COLGAN, Terence J., *et al.*
Title: METHODS FOR DETECTING MARKERS
ASSOCIATED WITH ENDOMETRIAL DISEASE OR
PHASE
Application No.: 10/584,207
Filed: June 23, 2006
International Application No. PCT/CA2004/002172

**STATEMENT BY PERSON BEING ADDED AS INVENTOR
(37 C.F.R. § 1.497(d))**


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.

Sir:

This communication is an attachment to a Declaration concurrently being filed pursuant to 35 U.S.C. 371 (c)(4) and 37 C.F.R. 1.497 in connection with the above-identified application.

I, Georg Diehl, residing at Rosenstrasse 13, D-79176 Weil am Rhein, Germany, who is being added as an inventor to correct the inventorship of this patent application do hereby declare that the inventorship error in failing to include my name as an inventor in International Application No. PCT/CA2004/002172 occurred without any deceptive intention on my part.

Date: Nov 7, 2007

Signature: 
Georg Diehl

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: COLGAN, Terence J., *et al.*
Title: METHODS FOR DETECTING MARKERS
ASSOCIATED WITH ENDOMETRIAL DISEASE OR
PHASE
Application No.: 10/584,207
Filed: June 23, 2006
International Application No. PCT/CA2004/002172

**CONSENT OF ASSIGNEES TO INVENTORSHIP CORRECTION
(37 C.F.R. § 1.497(d))**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.

Sir:

This communication is an attachment to a Declaration concurrently being filed pursuant to 35 U.S.C. § 371 (c)(4) and 37 C.F.R. § 1.497 in connection with the above-identified application which are assigned to the following three entities:

First Assignee: MOUNT SINAI HOSPITAL
Address: 600 University Avenue, Room 970 Toronto, Ontario
M5G 1X5, Canada
Second Assignee: UNIVERSITY HEALTH NETWORK
Address: 610 University Avenue
Toronto, Ontario M5G 2M9, Canada
Third Assignee: SIU, K. W. Michael
Address: 27 Cobblestone Drive
Toronto, Ontario M2J 2X6, Canada

The Assignees hereby consent to the correction of inventorship of this application by adding Leroi DeSouza, Georg Diehl and Jingzhong Guo as inventors who were erroneously omitted in International Application No. PCT/CA2004/002172, the omission of which was without deceptive intent.

The Assignees and York University hereby consent to the naming K.W. Michael Siu as an Applicant/Owner and not naming York University as an Applicant/Owner.


Attachments:


1. A statement under 37 CFR 3.73(b) by Mount Sinai Hospital indicating that the extent of its ownership interest in the above-identified application is _____% and/or as outlined in the Agreement between the Assignees dated _____ and being attached with a copy of an assignment from Terence J. Colgan to Mount Sinai Hospital

2. A statement under 37 CFR 3.73(b) by University Health Network indicating that the extent of its ownership interest in the above-identified application is 30% and/or as outlined in the Agreement between the Assignees dated Dec. 23/03 and being attached with a copy of an assignment from Alexander D. Romaschin

3. A statement under 37 CFR 3.73(b) by K. W. Michael Siu indicating that the extent of his ownership interest in the above-identified application is 40% and/or as outlined in the Agreement between the Assignees dated Dec. 23/03 and being attached with each copy of assignments (i) from Eric C. C. Yang to K. W. Michael Siu, (ii) from Leroi DeSouza to K. W. Michael Siu, (iii) from Georg Diehl to K. W. Michael Siu, and (iv) from Jingzhong Guo to K. W. Michael Siu

MOUNT SINAI HOSPITAL	By: _____ Name: Title:	Date:
UNIVERSITY HEALTH NETWORK	By: <u>Dr. A.D. Romaschin</u> Name: Dr. A.D. Romaschin Title: Division Head, Biochemistry	Date: <u>Nov 8/07</u>

SIU, K. W. MICHAEL	 K. W. Michael Siu	Date: Nov 2, 2007
YORK UNIVERSITY	David Phipps Director, Office of Research Services York University	Date:

SIU, K. W. MICHAEL	<hr/> K. W. Michael Siu	Date:
YORK UNIVERSITY	 <hr/> David Phipps Director, Office of Research Services York University	Date: Nov 15/07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: COLGAN, Terence J., *et al.*
Title: METHODS FOR DETECTING MARKERS
ASSOCIATED WITH ENDOMETRIAL DISEASE OR
PHASE
Application No.: 10/584,207
Filed: June 23, 2006
International Application No. PCT/CA2004/002172

**CONSENT OF ASSIGNEES TO INVENTORSHIP CORRECTION
(37 C.F.R. § 1.497(d))**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.

Sir:

This communication is an attachment to a Declaration concurrently being filed pursuant to 35 U.S.C. § 371 (c)(4) and 37 C.F.R. § 1.497 in connection with the above-identified application which are assigned to the following three entities:


First Assignee: MOUNT SINAI HOSPITAL
Address: 600 University Avenue, Room 970 Toronto, Ontario
M5G 1X5, Canada
Second Assignee: UNIVERSITY HEALTH NETWORK
Address: 610 University Avenue
Toronto, Ontario M5G 2M9, Canada
Third Assignee: SIU, K. W. Michael
Address: 27 Cobblestone Drive
Toronto, Ontario M2J 2X6, Canada

The Assignees hereby consent to the correction of inventorship of this application by adding Leroi DeSouza, Georg Diehl and Jingzhong Guo as inventors who were erroneously omitted in International Application No. PCT/CA2004/002172, the omission of which was without deceptive intent.

The Assignees and York University hereby consent to the naming K.W. Michael Siu as an Applicant/Owner and not naming York University as an Applicant/Owner.

Attachments:

1. A statement under 37 CFR 3.73(b) by Mount Sinai Hospital indicating that the extent of its ownership interest in the above-identified application is 30%.
2. A statement under 37 CFR 3.73(b) by University Health Network indicating that the extent of its ownership interest in the above-identified application is 30%.
3. A statement under 37 CFR 3.73(b) by K. W. Michael Siu indicating that the extent of his ownership interest in the above-identified application is 40%.

MOUNT SINAI HOSPITAL	By:  Name: Joan Sproul Title: Senior Vice-President, Finance	Date: 15 November, 2007
UNIVERSITY HEALTH NETWORK	By: _____ Name: _____ Title: _____	Date: _____
SIU, K. W. MICHAEL	_____ K. W. Michael Siu	Date: _____

YORK UNIVERSITY	<hr/> David Phipps Director, Office of Research Services York University	Date:
------------------------	---	--------------